Literature DB >> 6432171

Plasma lipids and insulin in gall stone disease: a case-control study.

R K Scragg, G D Calvert, J R Oliver.   

Abstract

Fasting plasma lipid and insulin concentrations were measured in 173 patients with gall stones and 284 hospital controls to investigate their relationship to this disease. Multivariate methods of analysis were used to estimate the net associations between individual plasma variables and the risk of developing gall stones. In both sexes increased plasma insulin values were associated with an increased risk of gall stones independently of plasma triglyceride values; increased plasma triglyceride concentrations were associated with an increased risk of gall stones in young subjects only; increased plasma total cholesterol concentrations were associated with a decreased risk of gall stones only after controlling for plasma insulin and triglyceride concentrations; while increased plasma high density lipoprotein cholesterol concentrations were associated with a decreased risk of gall stones, but were confounded by plasma insulin and triglyceride values. These associations were independent of obesity and dietary intake.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6432171      PMCID: PMC1442729          DOI: 10.1136/bmj.289.6444.521

Source DB:  PubMed          Journal:  Br Med J (Clin Res Ed)        ISSN: 0267-0623


  47 in total

1.  Serum cholesterol levels in Southwestern American Indians.

Authors:  M L Sievers
Journal:  J Chronic Dis       Date:  1968-05

2.  Serum cholesterol and incidence of gallstones. Analysis of one-year autopsy material.

Authors:  E Hove; T Geill
Journal:  Geriatrics       Date:  1968-01

3.  Association of a history of gallbladder disease with a reduced concentration of high-density-lipoprotein cholesterol.

Authors:  D B Petitti; G D Friedman; A L Klatsky
Journal:  N Engl J Med       Date:  1981-06-04       Impact factor: 91.245

4.  The epidemiology of gallbladder disease: observations in the Framingham Study.

Authors:  G D Friedman; W B Kannel; T R Dawber
Journal:  J Chronic Dis       Date:  1966-03

5.  Metabolism of free and esterified cholesterol and apolipoproteins of plasma low and high density lipoproteins.

Authors:  O W Portman; M Alexander; J P O'Malley
Journal:  Biochim Biophys Acta       Date:  1980-09-08

6.  Isocaloric exchange of dietary starch and sucrose in humans. II. Effect on fasting blood insulin, glucose, and glucagon and on insulin and glucose response to a sucrose load.

Authors:  S Reiser; H B Handler; L B Gardner; J G Hallfrisch; O E Michaelis; E S Prather
Journal:  Am J Clin Nutr       Date:  1979-11       Impact factor: 7.045

7.  Obese young men have elevated plasma estrogen levels but obese premenopausal women do not.

Authors:  B Zumoff; G W Strain; J Kream; J O'Connor; J Levin; D K Fukushima
Journal:  Metabolism       Date:  1981-10       Impact factor: 8.694

8.  Role of ovarian hormones in the long-term control of glucose homeostasis. Effects of insulin secretion.

Authors:  C J Bailey; H Ahmed-Sorour
Journal:  Diabetologia       Date:  1980-11       Impact factor: 10.122

9.  Serum lipid levels and hyperlipoproteinaemia in gallstone patients.

Authors:  J Ahlberg
Journal:  Acta Chir Scand       Date:  1979

10.  Lipid composition of bile in diabetics and obesity-matched controls.

Authors:  G B Haber; K W Heaton
Journal:  Gut       Date:  1979-06       Impact factor: 23.059

View more
  33 in total

1.  Cholelithiasic disease and associated factors in a Spanish population.

Authors:  F Devesa; J Ferrando; M Caldentey; A Borghol; M J Moreno; A Nolasco; J Moncho; J Berenguer
Journal:  Dig Dis Sci       Date:  2001-07       Impact factor: 3.199

2.  Impaired glucose tolerance, diabetes mellitus, and gallstone disease: an extended study of male self-defense officials in Japan.

Authors:  S Sasazuki; S Kono; I Todoroki; S Honjo; Y Sakurai; K Wakabayashi; M Nishiwaki; H Hamada; H Nishikawa; H Koga; S Ogawa; K Nakagawa
Journal:  Eur J Epidemiol       Date:  1999-03       Impact factor: 8.082

3.  Gallstones, serum lipids, and glucose tolerance among male officials of Self-Defense Forces in Japan.

Authors:  S Kono; S Kochi; S Ohyama; A Wakisaka
Journal:  Dig Dis Sci       Date:  1988-07       Impact factor: 3.199

Review 4.  Medical aspects of gallstones--1985: sixty years on.

Authors:  R H Dowling; D Gleeson
Journal:  Postgrad Med J       Date:  1985-10       Impact factor: 2.401

5.  Serum leptin levels and insulin resistance are associated with gallstone disease in overweight subjects.

Authors:  Nahum Méndez-Sánchez; Luisa-B Bermejo-Martínez; Yolanda Viñals; Norberto-C Chavez-Tapia; Irina Vander Graff; Guadalupe Ponciano-Rodríguez; Martha-H Ramos; Misael Uribe
Journal:  World J Gastroenterol       Date:  2005-10-21       Impact factor: 5.742

6.  Prospective study of malabsorption induced risk of gall stone formation in relation to fall in plasma cholesterol.

Authors:  T I Sørensen; B Andersen; E Hylander; L I Jensen; K Laursen; H C Klein
Journal:  Gut       Date:  1988-01       Impact factor: 23.059

Review 7.  [Dietetic influences on the formation and prevention of cholesterol gallstones].

Authors:  E A Trautwein
Journal:  Z Ernahrungswiss       Date:  1994-03

8.  Diet-induced type IV-like hyperlipidemia and increased body weight are associated with cholesterol gallstones in hamsters.

Authors:  K C Hayes; P Khosla; A Pronczuk
Journal:  Lipids       Date:  1991-09       Impact factor: 1.880

9.  Polymorphisms at cholesterol 7alpha-hydroxylase, apolipoproteins B and E and low density lipoprotein receptor genes in patients with gallbladder stone disease.

Authors:  Zhao-Yan Jiang; Tian-Quan Han; Guang-Jun Suo; Dian-Xu Feng; Sheng Chen; Xing-Xing Cai; Zhi-Hong Jiang; Jun Shang; Yi Zhang; Yu Jiang; Sheng-Dao Zhang
Journal:  World J Gastroenterol       Date:  2004-05-15       Impact factor: 5.742

10.  Association of apolipoprotein A1-C3 gene cluster polymorphisms with gallstone disease.

Authors:  Manjusha Dixit; Gourdas Choudhuri; Rajan Saxena; Balraj Mittal
Journal:  Can J Gastroenterol       Date:  2007-09       Impact factor: 3.522

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.